Walter U. Fries

Messina, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

Psychological adaptation and health-related quality of life in inflammatory bowel disease: a 5-year follow-up study.

Psychological adaptation and health-related quality of life in inflammatory bowel disease: a 5-year follow-up study.

Journal: Research in psychotherapy (Milano)

Published: August 18, 2026

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Journal: Advances in therapy

Published: March 21, 2026

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).

Journal: United European gastroenterology journal

Published: January 14, 2026

Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern.

Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern.

Journal: Drugs & aging

Published: October 26, 2025

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Journal: Journal of Crohn's & colitis

Published: October 13, 2025

TNF-α Quantification in Formalin-Fixed Paraffin-Embedded Tissues as a Predictive Biomarker in Ulcerative Colitis.

TNF-α Quantification in Formalin-Fixed Paraffin-Embedded Tissues as a Predictive Biomarker in Ulcerative Colitis.

Journal: Diagnostics (Basel, Switzerland)

Published: October 10, 2025

Inflammatory Bowel Disease Patients with a History of Cancer: Safety of Immunomodulators in a Multicenter Study.

Inflammatory Bowel Disease Patients with a History of Cancer: Safety of Immunomodulators in a Multicenter Study.

Journal: Cancers

Published: August 26, 2025

Vaccination Coverage in Adult Patients with Inflammatory Bowel Disease: Impact of a Tailored Vaccination Pathway Including COVID-19 and Herpes Zoster in a University Hospital Vaccination Center.

Vaccination Coverage in Adult Patients with Inflammatory Bowel Disease: Impact of a Tailored Vaccination Pathway Including COVID-19 and Herpes Zoster in a University Hospital Vaccination Center.

Journal: Vaccines

Published: August 16, 2025

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: June 12, 2025

Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction.

Upadacitinib-Induced Hemolysis in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency-A Possible Adverse Drug Reaction.

Journal: Pharmacology research & perspectives

Published: May 04, 2025

Management of bile acid diarrhea in Italy: a survey.

Management of bile acid diarrhea in Italy: a survey.

Journal: Internal and emergency medicine

Published: April 17, 2025

Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.

Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: March 08, 2025

Showing 1-12 of 106

Last Updated: 09/26/2026